123 related articles for article (PubMed ID: 23750898)
1. Two haemophilia patients with inhibitors who became ambulatory after physiotherapy under haemostatic cover with bypassing agents.
Kajiwara M; Shima M; Yoshioka A
Haemophilia; 2013 Sep; 19(5):e301-4. PubMed ID: 23750898
[No Abstract] [Full Text] [Related]
2. A case report of a premature infant with haemophilia A and factor VIII inhibitor.
Cartledge P; Deakin K; McKecknie L; Richards M
Haemophilia; 2011 Jul; 17(4):711-2. PubMed ID: 21371187
[No Abstract] [Full Text] [Related]
3. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
5. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography.
Sørensen B; Ingerslev J
Haemophilia; 2005 Nov; 11 Suppl 1():1-6. PubMed ID: 16219042
[TBL] [Abstract][Full Text] [Related]
6. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
[TBL] [Abstract][Full Text] [Related]
7. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors.
Rangarajan S; Yee TT; Wilde J
Haemophilia; 2011 Jan; 17(1):28-34. PubMed ID: 20642787
[TBL] [Abstract][Full Text] [Related]
8. Non-factor replacement therapy for haemophilia: a current update.
Franchini M; Mannucci PM
Blood Transfus; 2018 Sep; 16(5):457-461. PubMed ID: 29517971
[TBL] [Abstract][Full Text] [Related]
9. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors.
Stine KC; Shrum D; Becton DL
J Pediatr Hematol Oncol; 2007 Apr; 29(4):216-21. PubMed ID: 17414562
[TBL] [Abstract][Full Text] [Related]
10. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
11. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
Takedani H; Kawahara H; Kajiwara M
Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
[TBL] [Abstract][Full Text] [Related]
12. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
Teitel J; Berntorp E; Dolan G; Fischer K; Gringeri A; Kessler C; Lambert T; Leissinger C; Nemes L; Shima M
Haemophilia; 2011 May; 17(3):516-21. PubMed ID: 21371181
[TBL] [Abstract][Full Text] [Related]
13. [Laboratory monitoring of efficiency of different approaches to the therapy of patients with inhibitor form of haemophilia A].
Nabieva MI
Lik Sprava; 2009; (1-2):59-61. PubMed ID: 19953993
[TBL] [Abstract][Full Text] [Related]
14. How I treat inhibitors in haemophilia.
Makris M; Hay CR; Gringeri A; D'Oiron R
Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
[TBL] [Abstract][Full Text] [Related]
15. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
Hugenholtz GC; Luddington R; Baglin T
Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
[No Abstract] [Full Text] [Related]
16. Presence of thrombophilia and levels of coagulation factors, coagulation inhibitors and TAFI do not affect global haemostasis or bleeding phenotype in patients with haemophilia A.
Mikovic D; Pruner I; Antovic JP; Chaireti R
Thromb Res; 2019 Jan; 173():1-3. PubMed ID: 30447478
[No Abstract] [Full Text] [Related]
17. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
Kocher S; Asmelash G; Makki V; Müller S; Krekeler S; Alesci S; Miesbach W
Hamostaseologie; 2012; 32 Suppl 1():S39-42. PubMed ID: 22961330
[TBL] [Abstract][Full Text] [Related]
18. Importance of rapid bleeding control in haemophilia complicated by inhibitors.
Berntorp E
Haemophilia; 2011 Jan; 17(1):11-6. PubMed ID: 20565546
[TBL] [Abstract][Full Text] [Related]
19. Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
Hedner U
Haemophilia; 2010 Mar; 16(2):372-3. PubMed ID: 20028420
[No Abstract] [Full Text] [Related]
20. Haemophilia and inhibitors. 1: Diagnosis and treatment.
Mitchell J; Phillott A
Nurs Times; 2008 Jul 1-7; 104(26):26-7. PubMed ID: 18669400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
